Comparison of different treatment regimens in a case of homozygous familial hypercholesterolemia

被引:8
|
作者
Palcoux, JB [1 ]
Meyer, M
Jouanel, T
Vanlieferinghen, P
Malpuech, G
机构
[1] Hop Hotel Dieu, Dept Pediat, F-63058 Clermont Ferrand, France
[2] Hop Hotel Dieu, Biochem Lab, F-63058 Clermont Ferrand, France
来源
THERAPEUTIC APHERESIS | 2002年 / 6卷 / 02期
关键词
familial hypercholesterolemia; low-density lipoprotein apheresis;
D O I
10.1046/j.1526-0968.2002.00345.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The laboratory results of five periods of different treatment regimens were compared in a 19-year-old girl with homozygous familial hypercholesterolemia (FH): weekly low-density lipoprotein (LDL) apheresis sessions with dextran sulfate columns (LA 15, Kaneka Corporation, Osaka, Japan) without statin administration: weekly LDL apheresis with polyacrylate columns (DALI Fresenius Adsorber Technology. Bad Homburg. Germany) without statin: LDL apheresis as in Period 2 with 40 mg atorvastatin daily: LDL apheresis as in Period 2 with 80 mg atorvastatin daily and fortnightly LDL apheresis sessions with polyacrilate and administration of 80 mg atorvastatin daily. The five treatments were given in the above order. and each lasted at least 2 months. To compare the effectiveness of the different methods, the blood levels of total cholesterol. LDL-cholesterol and high-density lipoprotein (HDL)-cholesterol were measured before each session, and the percentage decreases in the blood levels of total cholesterol and LDL-cholesterol were recorded during sessions in Periods 1 and 2. In Periods 1 and 2. the biological effectiveness of LDL apheresis was comparable. Atorvastatin (40 mg daily) improved the blood levels of total cholesterol and LDL-cholesterol. but lowered HDL-cholesterol values. Increasing the daily dose of atorvastatin from 40 mg to 80 mg did not significantly improve LDL-cholesterol levels. When the time between two sessions was longer (Period 5). the total cholesterol and LDL-cholesterol values worsened and were comparable to those of Period 2 during which there was no atorvastatin treatment. In this case of homozygous FH. weekly sessions of LDL apheresis in association with atorvastatin at dose of 40 mg per day gave the best results.
引用
收藏
页码:136 / 139
页数:4
相关论文
共 50 条
  • [41] Homozygous familial hypercholesterolemia: Current perspectives on diagnosis and treatment
    Raal, Frederick J.
    Santos, Raul D.
    ATHEROSCLEROSIS, 2012, 223 (02) : 262 - 268
  • [42] Evinacumab: a new option in the treatment of homozygous familial hypercholesterolemia
    Pirillo, Angela
    Catapano, Alberico L.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2022, 22 (07) : 813 - 820
  • [43] Pregnancy in homozygous familial hypercholesterolemia-A case series
    Blaha, Milan
    Veletova, Katerina
    Blaha, Vladimir
    Lanska, Miriam
    Zak, Pavel
    THERAPEUTIC APHERESIS AND DIALYSIS, 2022, 26 : 89 - 96
  • [44] RESPONSE TO ALIROCUMAB IN HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: A CASE REPORT
    Chan, Melody Lok-Yi
    Shiu, Sammy
    Wong, Ying
    Tan, Kathryn
    ATHEROSCLEROSIS SUPPLEMENTS, 2018, 32 : 43 - 44
  • [45] Role of LDL apheresis in a case of homozygous familial hypercholesterolemia
    Naveen, Talakola
    Biswas, Ashutosh
    Wig, Naveet
    Soneja, Manish
    Jorwal, Pankaj
    Durga, Chitikela Sindhura
    Singla, Paras
    Chaudhary, Charusmita
    Baitha, Upendra
    DRUG DISCOVERIES AND THERAPEUTICS, 2019, 13 (01): : 59 - 61
  • [46] TREATMENT OF HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA WITH PORTACAVAL-SHUNT
    FORMAN, MB
    BAKER, SG
    MIENY, CJ
    JOFFE, BI
    SANDLER, MP
    MENDELSOHN, D
    SEFTEL, HC
    ATHEROSCLEROSIS, 1982, 41 (2-3) : 349 - 361
  • [47] Will evinacumab become the standard treatment for homozygous familial hypercholesterolemia?
    Doggrell, Sheila A.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (03) : 299 - 302
  • [48] Evidence for improved survival with treatment of homozygous familial hypercholesterolemia
    Belanger, Alexandre M.
    Akioyamen, Leo
    Alothman, Latifah
    Genest, Jacques
    CURRENT OPINION IN LIPIDOLOGY, 2020, 31 (04) : 176 - 181
  • [49] Lomitapide: A novel agent for the treatment of homozygous familial hypercholesterolemia
    Davis, Kyle A.
    Miyares, Marta A.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2014, 71 (12) : 1001 - 1008
  • [50] Challenges in The Treatment of Complex Cases of Homozygous Familial Hypercholesterolemia
    Mancioppi, Valentina
    Fornari, Elena
    Olivieri, Francesca
    Corradi, Massimiliano
    Morandi, Anita
    Maffeis, Claudio
    HORMONE RESEARCH IN PAEDIATRICS, 2024, 97 : 583 - 583